Rybrevant for atypical EGFR-mutated NSCLC, when administered in combination with LAZCLUZE® (lazertinib), demonstrates encouraging long-term outcomes in a highly challenging patient population. According to updated data from the Phase 1/1b CHRYSALIS-2 study released by Johnson & Johnson
, this frontline treatment combination achieved a median overall survival of nearly 3.5 years. These results contribute significantly to the expanding body of clinical evidence supporting the combination’s capacity to deliver highly durable survival benefits in advanced non-small cell lung cancer (NSCLC) management.
Patients diagnosed with atypical EGFR mutations face a substantial clinical hurdle because their tumors typically yield poorer outcomes than those with common mutations like exon 19 deletions or L858R substitutions. Representing roughly 10 to 20 percent of all global EGFR-mutated NSCLC cases, these atypical variants have historically had limited frontline options. In fact, the median overall survival under current standard-of-care single-agent treatments typically drops below two years, underlining a stark unmet need for more robust and long-lasting therapies in the primary care setting.
To address these aggressive disease drivers, the therapeutic regimen utilizes dual-targeting mechanisms to combat tumor growth and prevent therapy resistance. RYBREVANT® is an advanced bispecific antibody engineered to target both EGFR and mesenchymal-epithelial transition (MET) pathways simultaneously while actively engaging the patient’s immune system. When paired with LAZCLUZE®, an oral third-generation tyrosine kinase inhibitor (TKI), the combination introduces a powerful chemotherapy-free strategy designed to stop single-pathway resistance before it starts.
Clinical Efficacy Milestones of Rybrevant for atypical EGFR-mutated NSCLC
The long-term analysis of the CHRYSALIS-2 study highlighted unprecedented secondary survival endpoints for this patient cohort. The combination therapy achieved a precise median overall survival (mOS) of 41.0 months, representing a massive shift away from historical single-agent benchmarks. Longitudinal tracking further revealed landmark three-year and four-year overall survival rates of 55 percent and 46 percent respectively, demonstrating exceptional durability over extended periods.
In addition to the remarkable survival statistics, the combination maintained robust tumor control and high patient adherence rates. The trial documented a previously reported objective response rate (ORR) of 57 percent, showing rapid and effective tumor cytoreduction. Crucially, the long-term data showed that 41 percent of the patients managed to stay on the RYBREVANT® regimen for two years or longer, demonstrating consistent clinical activity and sustained tolerability across various atypical EGFR mutation subgroups.
For patients with non-small cell lung cancer harboring atypical EGFR-mutations, first-line treatment decisions are often clouded by uncertainty regarding the efficacy of currently available EGFR tyrosine kinase inhibitors.
Joel Neal, M.D., Ph.D
Primary and Secondary Efficacy Endpoints
| Efficacy Parameter | Clinical Value | Clinical Significance & Metrics |
| Objective Response Rate (ORR) | 57% | Confirmed baseline tumor reduction response rate |
| Median Overall Survival (mOS) | 41.0 Months (~3.5 Years) | Key secondary survival endpoint reached |
| 3-Year Overall Survival Rate | 55% | Long-term landmark patient survival metric |
| 4-Year Overall Survival Rate | 46% | Long-term landmark patient survival metric |
| Extended Treatment Retention | 41% | Proportion of patients remaining on therapy ≥ 2 Years |
Clinical Trial Context and Patient Profile Parameters
| Parameter Type | Specification Profile | Study Context Details |
| Clinical Study Name | CHRYSALIS-2 | Phase 1/1b clinical trial protocol |
| Atypical Mutation Prevalence | 10% to 20% | Percentage of all EGFR-mutated NSCLC cases |
| Historical Survival Baseline | < 24 Months (< 2 Years) | Median OS with traditional single-agent therapies |
| Combination Therapy Agents | RYBREVANT® + LAZCLUZE® | Bispecific antibody paired with 3rd-Gen oral TKI |
| Primary Therapeutic Targets | EGFR, MET, and Immune Engagement | Multitargeted biology addressing resistance pathways |
